Clinical Trial Update: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing safety, tolerability, and efficacy of IONIS-AGT-LRx in chronic heart failure with reduced ejection fraction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• IONIS-AGT-LRx (Angiotensinogen antisense oligonucleotide)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Chronic Heart Failure With Reduced Ejection Fraction | Phase 2 | Status: COMPLETED